Boston, MA, 07/15/2013 (nysepost) – During the last trading session, the shares of Achillion Pharmaceuticals (NASDAQ:ACHN) were bought by insiders. One of the most notable purchases was made by QVT Associates GP LLC which holds a 10% stake in Achillion Pharmaceuticals, having bought a total number of 390,944 shares for the price of $ 2,475,223. Achillion Pharmaceuticals is a company focused on infectious disease therapeutic area.
During the last trading session, the stock of Achillion Pharmaceuticals has shown an increase of 1.62% and was trading with an average volume of 1.59 million shares at the value of $ 6.29. During the past 12 months, Achillion Pharmaceuticals has generated an income of $ -49.70 million with sales of $ 0.10 million. For the past 12 months, the analytic ratios of the company are as follows: price to sales ratio and price to cash ratio were calculated as 5314.12 and 3.66 respectively. The return on equity ratio of Achillion Pharmaceuticals stood at -49.40% while its return on assets was -44.60%.
More recently, after the bell Monday, Achillion Pharmaceuticals, Inc. has made an announcement that the company’s drug, “sovaprevir” is placed on a clinical hold by FDA after elevations found in liver enzymes. Following this, stock of Achillion Pharmaceuticals has plunged to more than 10-month low.
Achillion Pharmaceuticals is a biopharmaceutical company which has its focus on the discovery and development of therapies for infectious diseases which include anti-virals for chronic hepatitis C infection and anti-bacterials for resistant bacterial infections. The company has four drug candidates in its pipeline against HCV treatment: ACH-1625 – currently in phase IIa clinical trial, ACH-2684 and ACH-2928 – currently in phase I clinical studies, ACH-3102 – currently in the preparation for IND-filing and for entering into phase I studies.
Achillion Pharmaceuticals has a pipeline of other drug candidates and is currently seeking for collaborative partners. The company did not find the resources to develop ACH-702 and ACH-2881 which are potential against resistant bacterial infections and elvucitabine against HIV infection.